Atopic eczema
BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7198.1600 (Published 12 June 1999) Cite this as: BMJ 1999;318:1600
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
The above article on atopic eczema (BMJ Vol 318 12 June 1999, page
1600-1604) fails to address the importance of the wet wrap technique 1,2
in the treatment of atopic eczema. Wet wraps play an important role in the
management of children with eczema, especially that which does not respond
to first line treatment with steroids and emollients. They are used in
hospitals and in the community and provide great relief to the pruritus
but the procedure requires considerable input from the dermatology unit
until the patients are confident in using this technique.
Goodyear et al3 reported a trial in which 30 children aged between 9
months and 16 years with a mean age of 5.5 years were treated with wet
wraps for a period ranging from 2 to 5 days. All the children responded
well to treatment and there were no relapses at the 2 week follow up
appointment. Unfortunately, there was no control study done at the same
time. Since most departments now are using the wet wrap technique as a
daily treatment for atopic eczema in their outpatient daily treatment
centres it is important that this treatment is not forgotten as an
adjuvant to topical steroids and emollients.
Clearly larger randomised trials are needed to establish the clinical
effectiveness of this age-old technique in the treatment of acute
erythrodermic and chronic lichenified atopic eczema.
Prakash Gowda, Specialist Registrar in Dermatology
Shernaz Walton, Consultant Dermatologist
Department of Dermatology
Princess Royal Hospital
Saltshouse Road
HULL HU8 9HE
References
1. Donald S. Know-how. Wet wraps in atopic eczema.
Nurs Times 1997 Oct 29-Nov 4; 93(44): 67-8.
2.Twitchen LJ, et al. Atopic eczema and wet wrap dressings.
Prof Nurse 1998 Nov;14(2): 113-6.
3. Goodyear HM, Spowart K, Harper JL. 'Wet wrap' dressings for the
treatment of atopic eczema in children. Br J Dermatol 1991; 125: 604.
Competing interests: No competing interests
Letter
ref: Charman C. Clinical evidence, Atopic eczema. BMJ 1999;318: 1600-
4.
Editor-I agree with the key message in the recent review of clinical
evidence in atopic eczema that the routine addition of antimicrobial
agents to topical steroid preparations provides no additional benefit .
However only a brief note was made of their use in clinically infected
eczema. I therefore thought the statement that "combinations of topical
antimicrobials and steroid are unlikely to be beneficial" is misleading,
and could be detrimental to the care of patients treated in primary care.
Atopic eczema frequently becomes infected, and deciding clinically if
acute eczema is infected can be difficult. Weeping yellow crusted lesions
are common, but pustulation is not. Swabbing, although helpful, does not
totally differentiate colonisation from infection. Even colonisation with
S. aureus may be detrimental, with the production of superantigens which
produce inflammation and exacerbation of eczema. Therefore general
practitioners should be on their guard for the presence of bacterial
infection in acute eczema and provide appropriate therapy.
Thomas F Poyner
General Practitioner and Clinical Assistant in Dermatology
Queens Park Medical Centre
Farrer Street
Stockton -on- Tees
TS18 2AW
Competing interests: No competing interests
Dear Sirs,
using idioms like "limited evidence", "insufficient evidence" etc.
looks like using a graduation for the level of evidence (like it is used
by the ACHPR /ACPR). But which are the distinct steps of this graduation ?
Which idiom do you use when no RCT oder other study can be found for an
clinical topic ?
Sincerely
Dr. Taplik
Competing interests: No competing interests
Vishnevsky liniment and ichthammol: on the perspectives of application in military medicine and other fields
Ichthammol (ichtyol, ammonium bituminosulfonate) is a product of dry distillation of oil shale. Vishnevsky liniment (VL) contains birch-tar, xeroformium (bismuth tribromophenolate) and castor oil. Both have been broadly used for topical medication in the former Soviet Union (SU). VL has been used for the management of wounds, burns, skin ulcers and suppurations. Ichthammol has been used for the treatment of skin diseases and burns; it was on the lists of medications for first-aid outfits and medical chests for construction brigades etc. Besides, in the former SU, ichthammol was used as an anti-inflammatory and antiseptic agent in urology, gynecology and other fields of medicine, e.g., for inflammatory conditions of the female genital tract including endometritis, for prostatitis [1-3], gonorrhea [4-6], and trichomoniasis [7], being inserted into the urethra, vagina, cervical canal, and rectum in the form of suppositories, tampons and instillations. Ichthammol and VL are discussed together because they contain polycyclic hydrocarbons [3,8,9], which is a group of substances that includes known carcinogens [10,11]. Besides, birch tar contains phenolic compounds [9] and methanol [12].
Xerophormium, a heterocyclic compound, has been used not only as an ingredient of VL but also in the rectal suppositories Anusol widely used in the former SU. Carcinogenicity of VL was not confirmed in an experiment on 116 mice [13]. However, considerable variation of the contents of known carcinogens (e.g. benzopyrene) in VL from different manufacturers was noticed [14]. Besides, tars of coal and wood (other than birch) origin were used for preparation of salves [14]. It appears probable that in conditions of insufficient quality control and mass production some manufacturers would replace birch-tar by other substances that can be more carcinogenic.
VL was broadly used in the Soviet army during the World War II [15]; the topic can gain significance today considering conflicts in Ukraine end elsewhere. Apart from antiseptic properties, among advantages of VL was pointed out an ability to accelerate tissue regeneration [2]. This latter quality is hardly understandable from the physiological viewpoint. In the author’s opinion, it could have originated from misconceived information about protruding skin lesions observed in tar workers [16]. Considering that the wounded are treated with VL on average for a relatively short time, the supposed carcinogenicity of VL can be more important for the medical personnel working with it. However, a prolonged application of VL e.g. for chronic skin ulcers, wounds or burns can be associated with enhanced risk of skin cancer, hematologic [17], and other malignancy. The same is apparently true in regard to the gynecological applications of ichthammol [1-6] in conditions of inefficient cervical cancer prevention in the former SU [18]. Considering the above, other antimicrobial agents should be used today. Antiseptics are preferable to topical antibiotics to prevent development of bacterial resistance in consequence of the mass application of antibiotics for topical medication [19]. The spectrum of antiseptics is broad; their comparison and selection for military and other applications [20] should be further investigated. The use of tar and ichthammol in dermathology e.g. for the treatment of atopic eczema [21] is a separate topic not discussed here.
References
1. State Drug Register of Russia. Moscow: Ministry of Health, 2001.
2. Mashkovskii MD. Drugs. Handbook for Physicians. 8th ed. Moscow: Meditsina, 1978.
3. Serebriakov LA. Ichtyol. Large Medical Encyclopaedia. 3rd ed. Vol. 9. Moscow: Soviet Encyclopaedia; 1978: 458-9.
4. Timoshenko LV. Practical gynecology. Kiev: Zdorov’ia, 1998.
5. Batkaev EA. Gonorrhoea in women. Moscow: Central Training Medical Institute, 1986.
6. Jargin SV. About the treatment of gonorrhea in the former Soviet Union. Dermatol Pract Concept. 2012;2(3):12.
7. Serdiukov VP, Demagin VA, Kulbyshev AF, et al. Ichtyol in the treatment of trichomoniasis in men. In: Materials of the IV Regional scientific conference of dermato-venerologists. Astrakhan, 1972: 68-70.
8. Regert M, Alexandre V, Thomas N, et al. Molecular characterisation of birch bark tar by headspace solid-phase microextraction gas chromatography-mass spectrometry: a new way for identifying archaeological glues. J Chromatogr A 2006; 1101:245-53.
9. Nozdrin VI, Albanova VI. Berestin (birch tar). Moscow: Retinoidy, 2011.
10. Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997; 8:444-72.
11. Bender HF, Eisenbarth Ph. Hazardous chemicals: control and regulation in the European market. Weinheim: Wiley-VCH, 2007.
12. Nordstrem EK. Manufacturing of birch tar. 2nd ed. Moscow: Local industry of RSFSR, 1944.
13. Faivishevskii VA, Shabad AL. Examination of possible blastomogenic action of Vishnevskii's ointment. Eksp Khirurgiia 1956; 1(6):53-7.
14. Shabad LM, Serkovskaia GS. Study of carcinogenic hydrocarbons in certain tar-containing ointments. Eksp Khir Anest 1971; (6):3-6.
15. Milashkin AG. Use of Vishnevskii liniment during the Second World War. Voen Med Zh 1982; (2):76.
16. Fisher RE. Occupational skin cancer in a group of tar workers. AMA Arch Ind Hyg Occup Med 1953; 7(1):12-8.
17. Heidel SM, MacWilliams PS, Baird WM, et al. Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12-dimethylbenz[a]anthracene. Cancer Res 2000; 60:3454-60.
18. Jargin SV. Perspectives of cervical cytology in Russia. Am J Obstet Gynecol. 2008; 199:e10.
19. O'Meara S, Al-Kurdi D, Ologun Y, et al. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2014; 1:CD003557.
20. Ward RS, Saffle JR. Topical agents in burn and wound care. Phys Ther 1995; 75:526-38.
21. Charman C. Clinical evidence: atopic eczema. BMJ. 1999;318(7198):1600-4.
Competing interests: No competing interests